Private Advisor Group LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 18,552 shares of the medical research company’s stock after acquiring an additional 179 shares during the quarter. Private Advisor Group LLC’s holdings in Thermo Fisher Scientific were worth $5,437,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Massey Quick Simon & CO. LLC acquired a new position in Thermo Fisher Scientific during the second quarter valued at $30,000. Redhawk Wealth Advisors Inc. acquired a new position in Thermo Fisher Scientific in the 2nd quarter worth about $31,000. Capital Advisors Ltd. LLC increased its position in Thermo Fisher Scientific by 250.0% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 140 shares of the medical research company’s stock worth $41,000 after purchasing an additional 100 shares during the last quarter. MRA Associates USA LLC acquired a new position in Thermo Fisher Scientific in the 2nd quarter worth about $43,000. Finally, Focused Wealth Management Inc acquired a new position in Thermo Fisher Scientific in the 2nd quarter worth about $44,000. Institutional investors and hedge funds own 88.17% of the company’s stock.
In other news, Director Jim P. Manzi sold 1,833 shares of the stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $272.93, for a total value of $500,280.69. Following the completion of the transaction, the director now directly owns 28,592 shares of the company’s stock, valued at approximately $7,803,614.56. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 2,271 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $298.00, for a total value of $676,758.00. Following the completion of the transaction, the chief executive officer now directly owns 283,502 shares of the company’s stock, valued at $84,483,596. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,104 shares of company stock valued at $15,418,539. 0.45% of the stock is currently owned by insiders.
Shares of TMO stock opened at $291.03 on Wednesday. The stock has a 50 day moving average of $281.75 and a two-hundred day moving average of $277.41. The company has a current ratio of 1.49, a quick ratio of 1.07 and a debt-to-equity ratio of 0.58. Thermo Fisher Scientific Inc. has a 12 month low of $208.34 and a 12 month high of $305.45. The company has a market capitalization of $119.20 billion, a P/E ratio of 26.17, a P/E/G ratio of 1.95 and a beta of 1.12.
Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.01 by $0.03. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The business had revenue of $6.32 billion during the quarter, compared to analysts’ expectations of $6.31 billion. During the same period in the prior year, the firm posted $2.75 EPS. Thermo Fisher Scientific’s quarterly revenue was up 3.9% compared to the same quarter last year. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 12.24 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Tuesday, September 17th will be issued a $0.19 dividend. The ex-dividend date is Monday, September 16th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.26%. Thermo Fisher Scientific’s payout ratio is presently 6.83%.
Several research firms have recently issued reports on TMO. Wolfe Research began coverage on Thermo Fisher Scientific in a research note on Thursday, May 30th. They set an “outperform” rating for the company. Credit Suisse Group reiterated a “buy” rating and set a $310.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Needham & Company LLC upped their price target on Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. UBS Group upped their price target on Thermo Fisher Scientific from $305.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, May 23rd. Finally, BTIG Research upped their price target on Thermo Fisher Scientific to $320.00 and gave the stock a “buy” rating in a research note on Thursday, May 23rd. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus price target of $303.17.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Further Reading: What is a good rate of return for a mutual fund?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.